A phase II study of spirogermanium in advanced large bowel cancer. An Eastern Cooperative Oncology Group study.

Thirty-one patients with advanced colorectal cancer were entered on a phase II study of spirogermanium. Of these, 23 received the drug at the dose of 200 mg/m2 intravenously (i.v.) over 4 h twice a week every week. There were 2 (9%) partial responses. No complete responses were noted. Two life-threatening and six severe toxicities were observed. We conclude that this drug has some activity against colorectal cancer.